Recent extremely meaningful positive changes in investment behavior have benefitted Collegium Pharmaceutical Inc (NASDAQ: COLL): the stock rose on very heavy volume, and the stock’s recent price rise disrupted its longer term downtrend.
Recent meaningful positive changes in fundamentals have benefitted Collegium Pharmaceutical Inc (NASDAQ: COLL): significant quarterly earnings acceleration occurred, and the consensus estimate for December, 2024 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, COLL is expected to continue to be a major Value Builder.
Collegium Pharmaceutical has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Collegium Pharmaceutical has a neutral Power Rating of 51 but a very high Appreciation Score of 98, producing the Highest Value Trend Rating.
Recent Price Action
On 11/10/23, Collegium Pharmaceutical Inc (NASDAQ: COLL) stock rose modestly by 0.3%, closing at $24.48. The stock has performed in line with the market over the last nine months and has risen 13.1% during the last week.
Be the first to comment